

SUPPLEMENTARY MATERIAL

Pharmacokinetic and Pharmacodynamic Relationship of Blinatumomab in Patients with Non-Hodgkin Lymphoma

Youssef Hijazi¹, Matthias Klinger¹, Andrea Kratzer¹, Benjamin Wu², Patrick A. Baeuerle¹, Peter Kufer¹, Andreas Wolf¹, Dirk Nagorsen² and Min Zhu^{2,*}

¹Amgen Research (Munich) GmbH, Munich, Germany; ²Amgen Inc., Thousand Oaks, CA, USA

Supplemental Table 1. Summary of blinatumomab dose levels and schedules administered as cIV infusion in the phase 1 study of relapsed/refractory NHL^a

	All patients (N=76)		
	Target dose, $\mu\text{g}/\text{m}^2/\text{day}$	Patients with initial 4-week treatment n	Patients with additional 4-week treatments n
Flat dosing	0.5	3	–
	1.5	6	–
	5	3	–
	15	13	1
	30	6	1
	60	9	3
	90	4	–
Stepwise dosing			
5–60 $\mu\text{g}/\text{m}^2/\text{day}$	60	6	2
15–60 $\mu\text{g}/\text{m}^2/\text{day}$	60	2	1
5–15–60 $\mu\text{g}/\text{m}^2/\text{day}$	60	24	3

cIV continuous intravenous, NHL non-Hodgkin lymphoma.

^aAdditional details about doses and dosing schedules are available in Goebeler M-E, et al. *J Clin Oncol.* 2016;34(10):1104-1111.